Phone -
Development of novel targeted therapies for neuroblastoma
Dylan aims to develop novel targeted therapies for neuroblastoma. Advances in medicinal chemistry have significantly accelerated the development of innovative drugs, such as proteolysis-targeting chimeras (PROTACs) and macrocyclic inhibitors, which offer several advantages over traditional small-molecule inhibitors. His work seeks to harness these technologies to target neuroblastoma drivers and ultimately lay the foundation for future clinical treatment strategies.